Yahoo
Stockholm - Delayed Quote SEK

Genovis AB (publ.) (GENO.ST)

21.25 -0.20 (-0.93%)
At close: 5:29:52 PM GMT+1
Chart Range Bar
Loading chart for GENO.ST
  • Previous Close 21.45
  • Open 21.40
  • Bid 21.05 x --
  • Ask 21.25 x --
  • Day's Range 20.75 - 21.55
  • 52 Week Range 15.64 - 23.65
  • Volume 86,769
  • Avg. Volume 181,077
  • Market Cap (intraday) 1.433B
  • Beta (5Y Monthly) 1.71
  • PE Ratio (TTM) 70.83
  • EPS (TTM) 0.30
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 33.00

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.

www.genovis.com

42

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

GENO.ST
0.00%
OMX Stockholm 30 Index (^OMX)
13.82%

1-Year Return

GENO.ST
7.81%
OMX Stockholm 30 Index (^OMX)
18.58%

3-Year Return

GENO.ST
54.25%
OMX Stockholm 30 Index (^OMX)
55.45%

5-Year Return

GENO.ST
74.09%
OMX Stockholm 30 Index (^OMX)
42.50%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 34.32M
Earnings 1.31M
Profit Margin 3.83%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
10M
20M
30M
40M
5.0%
10.0%
15.0%
20.0%
25.0%

Analyst Insights

View More

Analyst Price Targets

28.00
33.00 Average
21.25 Current
38.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.08%

  • Return on Assets (ttm)

    4.09%

  • Return on Equity (ttm)

    7.50%

  • Revenue (ttm)

    135.89M

  • Net Income Avi to Common (ttm)

    20.5M

  • Diluted EPS (ttm)

    0.30

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    157.19M

  • Total Debt/Equity (mrq)

    23.37%

  • Levered Free Cash Flow (ttm)

    30.13M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: